TSTakao Satou

Takao Satou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takao Satou has a total of 108 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Performance of Ultra-Rapid Idylla™ EGFR Mutation Test in Non-Small-Cell Lung Cancer and Its Potential at Clinical Molecular Screening

    by Kenichi Suda, Kazuko Sakai, Tatsuo Ohira, Takaaki Chikugo, Takao Satou, Jun Matsubayashi, Toshitaka Nagao, Norihiko Ikeda, Yasuhiro Tsutani, Tetsuya Mitsudomi, et al.

    Background: The Idylla™ EGFR Mutation Test is an ultra-rapid single-gene test that detects epidermal growth factor receptor (EGFR) mutations using formalin-fixed paraffin-embedded specimens. Here, we compared the performance of the Idylla EGFR Mutation Test with the Cobas® EGFR Mutation Test v2. Methods: Surgically resected NSCLC specimens obtained at two Japanese institutions (N = 170) were examined. The Idylla EGFR Mutation Test and the Cobas EGFR Mutation Test v2 were performed independently and the results were compared. For discordant cases, the Ion AmpliSeq Colon and Lung Cancer Research Panel V2 was performed. Results: After the exclusion of five inadequate/invalid samples, 165 cases were evaluated. EGFR mutation analysis revealed 52 were positive and 107 were negative for EGFR mutation in both assays (overall concordance rate: 96.4%). Analyses of the six discordant cases revealed that the Idylla EGFR Mutation Test was correct in four and the Cobas EGFR Mutation Test v2 was correct in two. In a trial calculation, the combination of the Idylla EGFR Mutation Test followed by a multi-gene panel test will reduce molecular screening expenses if applied to a cohort with EGFR mutation frequency >17.9%. Conclusions: We demonstrated the accuracy and potential clinical utility of the Idylla EGFR Mutation Test as a molecular screening platform in terms of turnaround time and molecular testing cost if applied to a cohort with a high EGFR mutation incidence (>17.9%).


  • Open Access

    The HGF/Met/NF-κB Pathway Regulates RANKL Expression in Osteoblasts and Bone Marrow Stromal Cells

    by Masanobu Tsubaki, Shiori Seki, Tomoya Takeda, Akiko Chihara, Yuuko Arai, Yuusuke Morii, Motohiro Imano, Takao Satou, Kazunori Shimomura, Shozo Nishida

    Multiple myeloma (MM)-induced bone disease occurs through hyperactivation of osteoclasts by several factors secreted by MM cells. MM cell-secreted factors induce osteoclast differentiation and activation via direct and indirect actions including enhanced expression of receptor activator of nuclear factor κB ligand (RANKL) in osteoblasts and bone marrow stromal cells (BMSCs). Hepatocyte growth factor (HGF) is elevated in MM patients and is associated with MM-induced bone disease, although the mechanism by which HGF promotes bone disease remains unclear. In the present study, we demonstrated that HGF induces RANKL expression in osteoblasts and BMSCs, and investigated the mechanism of induction. We found that HGF and MM cell supernatants induced RANKL expression in ST2 cells, MC3T3-E1 cells, and mouse BMSCs. In addition, HGF increased phosphorylation of Met and nuclear factor κB (NF-κB) in ST2 cells, MC3T3-E1 cells, or mouse BMSCs. Moreover, Met and NF-κB inhibitors suppressed HGF-induced RANKL expression in ST2 cells, MC3T3-E1 cells, and mouse BMSCs. These results indicated that HGF promotes RANKL expression in osteoblasts and BMSCs via the Met/NF-κB signaling pathway, and Met and NF-κB inhibitors suppressed HGF-induced RANKL expression. Our findings suggest that Met and NF-κB inhibitors are potentially useful in mitigating MM-induced bone disease in patients expressing high levels of HGF.


  • Open Access

    Dasatinib reverses drug resistance by downregulating MDR1 and Survivin in Burkitt lymphoma cells

    by Mitsuki Tabata, Masanobu Tsubaki, Tomoya Takeda, Keisuke Tateishi, Katsumasa Tsurushima, Motohiro Imano, Takao Satou, Toshihiko Ishizaka, Shozo Nishida

    Background: Current chemotherapies for Burkitt lymphoma (BL) have dramatically improved its clinical outcome. However, chemoresistance can lead to chemotherapy failure and very poor prognosis; thus, novel strategies are urgently required for patients with drug-resistant BL. To investigate the mechanisms underlying drug resistance in BL, we established drug-resistant BL cell lines: HS-Sultan/ADM (adriamycin-resistant), HS-Sultan/VCR (vincristine-resistant), HS-Sultan/DEX (dexamethasone-resistant), and HS-Sultan/L-PAM (melphalan-resistant). Methods: Drug transporter and survival factor expression were investigated the using western blotting and real time polymerase chain reaction. Cell survival was analyzed by trypan blue dye exclusion method. Results: The established cell lines acquired cross-resistance to adriamycin, vincristine, dexamethasone, and melphalan and exhibited 50% inhibitory concentration values 106-, 40-, 81-, and 45-fold higher than the parental cell lines, respectively. We found that protein and mRNA expression of MDR1 and Survivin were higher in drug-resistant BL cells than in the parent cells. Treatment with verapamil, an MDR1 inhibitor, or Survivin siRNA alongside each anti-cancer drug suppressed the proliferation of all drug-resistant BL cells. Src kinase activity was higher in all resistant cell lines than the parental cells; suppressing Src with dasatinib restored drug sensitivity by reducing MDR1 and Survivin expression. Conclusions: MDR1 and Survivin upregulation are responsible for resistance to conventional drugs and dasatinib can restore drug sensitivity by reducing MDR1 and Survivin expression in drug-resistant BL cells. Src inhibitors could therefore be a novel treatment strategy for patients with drug resistant BL.


  • Open Access

    Overactivation of Akt Contributes to MEK Inhibitor Primary and Acquired Resistance in Colorectal Cancer Cells

    by Masanobu Tsubaki, Tomoya Takeda, Masaki Noguchi, Minami Jinushi, Shiori Seki, Yuusuke Morii, Kazunori Shimomura, Motohiro Imano, Takao Satou, Shozo Nishida

    RAS and BRAF-mutated colorectal cancers are associated with resistance to chemotherapy and poor prognosis, highlighting the need for new therapeutic strategies. Although these cancers sometimes respond to mitogen activated protein kinase kinase (MEK) inhibitor treatment, they often acquire resistance via mechanisms, which are poorly understood. Here, we investigated the mechanism of MEK inhibitor resistance in primary- and acquired-resistant cells. Cell viability was examined using the trypan blue dye exclusion assay. Protein expression was analyzed by western blotting. Somatic mutations in colorectal cancer cells were investigated using the polymerase chain reaction array. PD0325901 and trametinib induced cell death in LoVo and Colo-205 cells but not in DLD-1 and HT-29 cells, which have a PIK3CA mutation constitutively activating Akt and NF-κB. Treatment with PD0325901 and trametinib suppressed ERK1/2 activation in all four cell lines but only induced Akt and NF-κB activation in DLD-1 and HT-29 cells. Inhibition of Akt but not NF-κB, overcame MEK inhibitor resistance in DLD-1 and HT-29 cells. Acquired-resistant LoVo/PR, Colo-205/PR and LoVo/TR cells have constitutively active Akt due to a M1043V mutation in the kinase activation loop of PIK3CA and Akt inhibitor resensitized these cells to MEK inhibitor. These results demonstrate that the overactivation of Akt plays a critical role in MEK inhibitor primary and acquired resistance and implicate combined Akt/MEK inhibition as a potentially useful treatment for RAS/BRAF-mutated colorectal cancer.


  • PS 07-18 HEART-BOUND ADIPONECTIN, NOT SERUM ADIPONECTIN, CORRELATES WITH CARDIAC HYPERTROPHY IN STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RATS

    by Takao Inoue, Kumiko Takemori, Nobuyuki Muzuguchi, Masatomo Kimura, Takaaki Chikugo, Man Hagiyama, Azusa Yoneshige, Tatsufumi Mori, Takashi Kometani, Tatsuki Itoh, et al.

    The relationship between serum adiponectin concentration and hypertension or cardiac hypertrophy is still controversial. We have previously proposed that tissue-bound adiponectin possibly plays an important role against metabolic syndrome. In this study, we investigated the relationship between heart-bound adiponectin and hypertension or cardiac hypertrophy, compared with serum adiponectin in hypertensive rats. Six-, 12-, and 20-week-old Wistar-Kyoto rats (WKY); 2 subspecies (strains C and B2, characterized by having lower and higher blood pressure, respectively) of spontaneously hypertensive rats (SHR); and stroke-prone SHR (SHRSP) were used. Blood pressure, heart/body ratio, serum adiponectin, and heart-bound adiponectin were measured. Histopathological analyses of the heart were also carried out. The heart/body ratio strongly correlated with blood pressure in 12- and 20-week-old rats, as expected. Serum adiponectin concentration, however, was positively correlated with blood pressure in 12- and 20-week-old rats, and the heart/body ratio and heart muscle cross-sectional area in 20-week-old rats, indicating that there is no relationship between serum adiponectin and blood pressure or cardiac hypertrophy in these rats. In contrast, heart-bound adiponectin in SHRSP was significantly decreased than that in other species of all ages. This results from a decrease in T-cadherin expression, which induces adiponectin binding to tissues. Heart-bound adiponectin inversely correlated with the heart muscle cross-sectional area, but not with blood pressure, indicating that heart-bound adiponectin is more closely related with cardiac hypertrophy than serum adiponectin concentration in these rats. Some researches have reported that serum adiponectin concentration is a useful parameter for evaluating the health condition. Some patients, however, showed hypertension and cardiac hypertrophy despite having high adiponectin concentrations in blood. Our results suggest the possibility that such patients would have decreased heart-bound adiponectin mediated by T-cadherin, and a high adiponectin concentration in blood.

  • Cytology of bronchoalveolar lavage fluid can aid in the diagnosis of allergic bronchopulmonary aspergillosis

    by Ayaka Kobayashi, Masatomo Kimura, Kiyofumi Ueda, Chikoto Tanaka, Eisuke Enoki, Takaaki Chikugo, Tadao Uesugi, Takao Satou

  • Open Access

    Nitrogen-containing bisphosphonates inhibit RANKL- and M-CSF-induced osteoclast formation through the inhibition of ERK1/2 and Akt activation

    by Masanobu Tsubaki, Makiko Komai, Tatsuki Itoh, Motohiro Imano, Kotaro Sakamoto, Hirotaka Shimaoka, Tomoya Takeda, Naoki Ogawa, Kenji Mashimo, Daiichiro Fujiwara, et al.

    Bisphosphonates are an important class of antiresorptive drugs used in the treatment of metabolic bone diseases. Recent studies have shown that nitrogen-containing bisphosphonates induced apoptosis in rabbit osteoclasts and prevented prenylated small GTPase. However, whether bisphosphonates inhibit osteoclast formation has not been determined. In the present study, we investigated the inhibitory effect of minodronate and alendronate on the osteoclast formation and clarified the mechanism involved in a mouse macrophage-like cell lines C7 and RAW264.7.


  • Usefulness of touch imprint cytology with immunocytochemistry of sentinel lymph node metastases in breast cancer

    by Kiyofumi Ueda, Kanako Mori, Ayaka Kobayashi, Yuko Teshima, Chikoto Dobashi, Tadao Uesugi, Masatomo Kimura, Osamu Maenishi, Takao Satou

  • Open Access

    Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines

    by Masanobu Tsubaki, Makiko Komai, Shin-Ichiro Fujimoto, Tatsuki Itoh, Motohiro Imano, Kotaro Sakamoto, Hirotaka Shimaoka, Tomoya Takeda, Naoki Ogawa, Kenji Mashimo, et al.

    Background: Increased motility and invasiveness of cancer cells are reminiscent of the epithelial-mesenchymal transition (EMT), which occurs during cancer progression and metastasis. Recent studies have indicated the expression of receptor activator of nuclear factor-κB (RANK) in various solid tumors, including breast cancer. Although activation of the RANK ligand (RANKL)/RANK system promotes cell migration, metastasis, and anchorage-independent growth of tumor-initiating cells, it remains to be investigated if RANKL induces EMT in breast cancer cells. In this study, we investigated whether RANKL induces EMT in normal breast mammary epithelial cells and breast cancer cells, and the mechanism underlying such induction. Methods: Expression levels of vimentin, N-cadherin, E-cadherin, Snail, Slug, and Twist were examined by real-time polymerase chain reaction. Cell migration and invasion were assessed using Boyden chamber and invasion assays, respectively. The effects of RANKL on signal transduction molecules were determined by western blot analyses. Results: We found that stimulation by RANKL altered the cell morphology to the mesenchymal phenotype in normal breast epithelial and breast cancer cells. In addition, RANKL increased the expression levels of vimentin, N-cadherin, Snail, and Twist and decreased the expression of E-cadherin. We also found that RANKL activated nuclear factor-κB (NF-κB), but not extracellular signal-regulated kinase 1/2, Akt, mammalian target of rapamycin, c-Jun N-terminal kinase, and signal transducer and activator of transcription 3. Moreover, dimethyl fumarate, a NF-κB inhibitor, inhibited RANKL-induced EMT, cell migration, and invasion, and upregulated the expressions of Snail, Twist, vimentin, and N-cadherin. Conclusions: The results indicate that RANKL induces EMT by activating the NF-κB pathway and enhancing Snail and Twist expression. These findings suggest that the RANKL/RANK system promotes tumor cell migration, invasion, and metastasis via the induction of EMT.


    • 1 April 2013
      • Vol. 33  (4) , 1439-46

    Establishment of a novel model of peritoneal carcinomatosis of the peritoneal extension type.

    by Motohiro Imano, Tatsuki Itoh, Takao Satou, Akira Kido, Masahiro Tsubaki, Atsushi Yasuda, Hiroaki Kato, Haruhiko Imamoto, Shozo Nishida, Hiroshi Furukawa, et al.

    Patients with scirrhous carcinoma of the gastrointestinal tract frequently develop peritoneal carcinomatosis-particularly of the peritoneal extension type (PET), which has a bad prognosis. We developed a novel animal model, suitable for testing treatments for PET. In order to develop the model, we scraped the entire peritoneum of Fischer 344 rats with sterile cotton swabs and injected 1 × 10(6) cells of the RCN-9 cell type into the peritoneal cavity. In the novel experimental model, RCN-9 cells adhered only to the exposed basement membrane. The submesothelial layer and fibroblasts in the submesothelial layer grew and increased to a maximum at day 7, then decreased during late-phase peritoneal carcinomatosis. At day 14, RCN-9 cells coated the peritoneum in a manner similar to PET. We successfully established a novel animal model of peritoneal carcinomatosis that mimics clinicopathological features of PET. Fibroblasts in the submesothelial layer potentially play an important role in peritoneal carcinomatosis.